Evidence map›Paper›PMID 33377660›Full record

ArticleClinical and translational medicine2020

Definition of erythroid cell-positive blood transcriptome phenotypes associated with severe respiratory syncytial virus infection.

Darawan Rinchai, Matthew C Altman, Oceane Konza, Signe Hässler, Federica Martina, Mohammed Toufiq, Mathieu Garand, Basirudeen Syed Ahamed Kabeer, Karolina Palucka, Asuncion Mejias and 5 more

Open access · goldAbstract read
In one paragraph

Article in Clinical and translational medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
3.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 45 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Hematopoietic responses to SARS-CoV-2 infection.Cellular and molecular life sciences : CMLS · 2022
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 4 countries.

Darawan RinchaiSidra Medicine, Doha, Qatar.ORCID https://orcid.org/0000-0001-8851-7730
Matthew C AltmanBenaroya Research Institute, Seattle, Washington.
Oceane KonzaBiotherapy (CIC-BTi) and Inflammation-Immunopathology-Biotherapy Department (i2B), AP-HP, Hôpital Pitié-Salpêtrière, Paris, France.
Signe HässlerBiotherapy (CIC-BTi) and Inflammation-Immunopathology-Biotherapy Department (i2B), AP-HP, Hôpital Pitié-Salpêtrière, Paris, France.
Federica MartinaBiotherapy (CIC-BTi) and Inflammation-Immunopathology-Biotherapy Department (i2B), AP-HP, Hôpital Pitié-Salpêtrière, Paris, France.
Mohammed ToufiqSidra Medicine, Doha, Qatar.
Mathieu GarandSidra Medicine, Doha, Qatar.
Basirudeen Syed Ahamed KabeerSidra Medicine, Doha, Qatar.
Karolina PaluckaJackson Laboratory for Genomic Medicine, Farmington, Connecticut.
Asuncion MejiasDivision of Infectious Diseases, Nationwide Children's Hospital, Columbus, Ohio.
Octavio RamiloDivision of Infectious Diseases, Nationwide Children's Hospital, Columbus, Ohio.
Davide BedognettiSidra Medicine, Doha, Qatar.
Encarnita Mariotti-FerrandizImmunology-Immunopathology-Immunotherapy (i3), Sorbonne Université, INSERM, Paris, France.
David KlatzmannBiotherapy (CIC-BTi) and Inflammation-Immunopathology-Biotherapy Department (i2B), AP-HP, Hôpital Pitié-Salpêtrière, Paris, France.
Damien ChaussabelSidra Medicine, Doha, Qatar.
Qatar Airways (Qatar) · QAInserm · FRNationwide Children's Hospital · USSorbonne Université · FRJackson Laboratory · USVirginia Mason Medical Center · US

Funding

Project 3: Dr. LiP01AI112524 · NIAID · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI LI, JIANRONG · 2015 to 2019
$6.8M
Respiratory Syncytial Virus Targeting of the Human Airway EpitheliumR01AI093848 · NIAID · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI PEEPLES, MARK E. · 2012 to 2023
$3.8M
NIAID NIH HHS P01 AI112524NIAID NIH HHS R01 AI093848
6 · The paper itself

Abstract

Biomarkers to assess the risk of developing severe respiratory syncytial virus (RSV) infection are needed. We conducted a meta-analysis of 490 unique profiles from six public RSV blood transcriptome datasets. A repertoire of 382 well-characterized transcriptional modules was used to define dominant host responses to RSV infection. The consolidated RSV cohort was stratified according to four traits: "interferon response" (IFN), "neutrophil-driven inflammation" (Infl), "cell cycle" (CC), and "erythrocytes" (Ery). We identified eight prevalent blood transcriptome phenotypes, of which three Ery+ phenotypes comprised higher proportions of patients requiring intensive care. This finding confirms on a larger scale data from one of our earlier reports describing an association between an erythrocyte signature and RSV disease severity. Further contextual interpretation made it possible to associate this signature with immunosuppressive states (late stage cancer, pharmacological immunosuppression), and with a population of fetal glycophorin A+ erythroid precursors. Furthermore, we posit that this erythrocyte cell signature may be linked to a population of immunosuppressive erythroid cells previously described in the literature, and that overabundance of this cell population in RSV patients may underlie progression to severe disease. These findings outline potential priority areas for biomarker development and investigations into the immune biology of RSV infection. The approach that we developed and employed here should also permit to delineate prevalent blood transcriptome phenotypes in other settings.

Identifiers

PMID33377660
PMCPMC7733317
OpenAlexW3110809804

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.